Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDR001 vs investigator's choice chemotherapy in recurrent/metastatic nasopharyngeal carcinoma
CTR20170837Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of spartalizumab in nasopharyngeal carcinoma (NPC), sponsored by Novartis. Started Jan 2018; status: completed.
02
Drugs
spartalizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on CTR20170837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170837.